wildwilly
02-15-2008, 10:18 AM
Q Therapeutics Announces Series B Investment
SALT LAKE CITY--(BUSINESS WIRE)--Feb 15, 2008 - Q Therapeutics, Inc., a biotechnology company pursuing cell-based therapies for the central nervous system (CNS), announced today that it has closed on a first tranche of its $15 million Series B financing. The round was led by vSpring Capital; other investors include Invitrogen Corporation, Epic Ventures (Formerly Wasatch Venture Fund), Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.
Q is conducting preclinical studies to support the filing of an Investigational New Drug Application with the FDA using Q-Cells(TM) (neural glial cells) for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis (MS). Clinical trials are anticipated at Johns Hopkins in 2009.
"Q is very pleased to add Invitrogen as an investor, along with the continued support of vSpring, Wasatch and Toucan," said Deborah Eppstein, Ph.D., President & CEO of Q Therapeutics. "This investment will help accelerate our efforts to bring important new treatments to the clinic for these extremely debilitating neurodegenerative diseases. As a leader in providing many of the necessary tools for stem cell research and production, Invitrogen's participation will further enhance our development going forward."
more:http://www.medadnews.com/News/Index.cfm?articleid=515753
SALT LAKE CITY--(BUSINESS WIRE)--Feb 15, 2008 - Q Therapeutics, Inc., a biotechnology company pursuing cell-based therapies for the central nervous system (CNS), announced today that it has closed on a first tranche of its $15 million Series B financing. The round was led by vSpring Capital; other investors include Invitrogen Corporation, Epic Ventures (Formerly Wasatch Venture Fund), Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.
Q is conducting preclinical studies to support the filing of an Investigational New Drug Application with the FDA using Q-Cells(TM) (neural glial cells) for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis (MS). Clinical trials are anticipated at Johns Hopkins in 2009.
"Q is very pleased to add Invitrogen as an investor, along with the continued support of vSpring, Wasatch and Toucan," said Deborah Eppstein, Ph.D., President & CEO of Q Therapeutics. "This investment will help accelerate our efforts to bring important new treatments to the clinic for these extremely debilitating neurodegenerative diseases. As a leader in providing many of the necessary tools for stem cell research and production, Invitrogen's participation will further enhance our development going forward."
more:http://www.medadnews.com/News/Index.cfm?articleid=515753